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Abstract
The extracellular matrix of epithelial tumors undergoes structural remodeling during periods of
uncontrolled growth, creating regional heterogeneity and torsional stress. How matrix integrity is
maintained in the face of dynamic biophysical forces is largely undefined. Here we investigated the
role of fibulin-2, a matrix glycoprotein that functions biomechanically as an inter-molecular clasp and
thereby facilitates supra-molecular assembly. Fibulin-2 was abundant in the extracellular matrix of
human lung adenocarcinomas and was highly expressed in tumor cell lines derived from mice that
develop metastatic lung adenocarcinoma from co-expression of mutant K-ras and p53. Loss-of-
function experiments in tumor cells revealed that fibulin-2 was required for tumor cells to grow and
metastasize in syngeneic mice, a surprising finding given that other intra-tumoral cell types are known
to secrete fibulin-2. However, tumor cells grew and metastasized equally well in Fbln2-null and -wild-
type littermates, implying that malignant progression was dependent specifically upon tumor cell-
derived fibulin-2, which could not be offset by other cellular sources of fibulin-2. Fibulin-2 deficiency
impaired the ability of tumor cells to migrate and invade in Boyden chambers, to create a stiff
extracellular matrix in mice, to cross-link secreted collagen, and to adhere to collagen. We conclude
that fibulin-2 is a driver of malignant progression in lung adenocarcinoma and plays an unexpected
role in collagen cross-linking and tumor cell adherence to collagen.
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Introduction
The extracellular matrix of epithelial tumors has
features that differ sharply from those of adjacent
tissue stroma [1]. Composed of a three-dimensional,
collagen-rich scaffold that serves as a structural
backbone for attached glycoproteins, sulfated
proteoglycans, and loosely-tethered peptide ligands,
tumor extracellular matrix evolves during malignant
progression, developing collagen-dense fibrotic foci and
enhanced stromal stiffness, which correlate with
adverse prognosis and a higher risk of metastasis [2].
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Tumor cells are important regulators of the tumor
matrix; they secrete diverse intrinsic matrix molecules
that integrate into the matrix scaffold and, in turn,
serve as ligands for integrin receptors that drive tumor
cell migration and invasion [3,4]. These findings
support a bi-directional model in which tumor cells
regulate the biochemical and biophysical properties of
surrounding matrix, which governs tumor cell biological
properties.
How tumor cells maintain extracellular matrix
integrity in the face of dynamic matrix biochemical and
biophysical forces is unclear. The fibulin gene family
members (FBLN1-5) encode glycoproteins that play a
central role in matrix stabilization by forming
homodimeric complexes that fold into 3- or 4-armed
structures, functioning as an inter-molecular clasp or
buckle that stabilizes matrix macromolecules, including
tropo-elastin fibers, microfibrils, and matrix-
proteoglycan complexes [5–8]. Studies on mice
deficient in fibulin family members have revealed a
prominent role for fibulins in tissue repair. Fbln2-null
mice have a normal lifespan under basal conditions and
display no ultrastructural defects in extracellular matrix
[9]. However, when stressed by myocardial infarction,
Fbln2-null mice develop a phenotype of reduced
cardiac tissue remodeling, attenuated TGF-β signaling
within damaged cardiac tissues, and significantly
improved survival [9], implying that fibulin-2 is required
for repair of tissues damaged by hypoxic stress, a
known driver of malignant progression of epithelial
tumors [9]. Supporting a potential role for fibulin-2 in
malignant progression, global transcriptomic profiling
of diverse types of human adenocarcinoma revealed
that fibulin-2 was more highly expressed in metastatic
tumors than it was at primary sites [10], and a
proteomic screen of highly and poorly metastatic tumor
cell lines derived from mice that develop lung
adenocarcinoma owing to co-expression of KrasG12D and
Trp53R172HΔG (designated “KP” cells and mice,
respectively) revealed that fibulin-2 was preferentially
expressed in highly metastatic cells [11]. On the basis
of these findings, here we posited that fibulin-2 drives
malignant progression by stabilizing tumor
extracellular matrix and tested this hypothesis by
performing correlative studies on human lung
adenocarcinomas and loss-of-function experiments on
KP cells.
Materials and Methods
Immunohistochemistry
Mouse and human tissue specimens were fixed in
10% formalin and embedded in paraffin. Five µm
paraffin sections were de-paraffinized with xylene and
rehydrated with ethanol. Sections were then incubated
in antigen retrieval solution (DAKO, Carpinteria, CA) for
20 minutes at 95°C followed by rinsing and blocking of
endogenous peroxidase with 3% H2O2 in cold methanol
for 20 minutes. Slides were rinsed and incubated in
blocking buffer (5% BSA, 1% Skim Milk, 0.05% Triton
X-100 in PBS) for 1 hour at room temperature. Sections
were incubated overnight in a humidified chamber with
antibodies against fibulin-2 (Novus Biologicals,
Littleton, CO) at 1:250 dilution and then incubated with
donkey anti-rabbit-HRP (Jackson ImmunoResearch,
West Grove, PA) diluted 1:500 for 1 hour at room
temperature. Slides were developed 3 to 5 minutes in
liquid DAB substrate solution (DAKO) and
counterstained with Meyer’s hematoxylin. Images were
acquired using an Olympus IX71 inverted fluorescent
microscope.
Fibulin-2 expression in human lung
adenocarcinomas
Immunohistochemical studies were carried out on
tumor tissue specimens obtained from 46 surgically
resected human lung adenocarcinomas, stages I-III,
resected with curative intent. All cases were fully
annotated for demographic variables, pathologic stage,
smoking status and clinical outcome. Fibrillar and
fibrous fibulin-2 staining was quantified separately in
tumor, adjacent normal lung parenchyma, and lung
tissue scars. The distribution of fibulin-2 expression
was quantified in the peripheral areas (defined as the
~25% peripheral portion of the tumors) and central
areas (defined as the ~75% central portion of the
tumors).
Murine lung adenocarcinoma cell lines
Murine lung adenocarcinoma cell lines (307P, 393P,
412P, 344SQ, 531LN2, 531LN3, and 344P) were
isolated and established from primary or metastatic
tumors of KP mice as described previously [12]. Cell
lines were named according to the mouse number and
site of derivation (e.g., 344SQ cells were from
subcutaneous metastatic tumors of mouse 344). These
cells have alveolar type II cell properties and variable
propensities to undergo epithelial-to-mesenchymal
transition and metastasize following injection into
syngeneic mice [12]. Given that these murine cell lines
are syngeneic, there are no reliable genotypic assays
(e.g. DNA fingerprinting) for verification of cell line
identity.
Transfection of Fbln2 short hairpin RNAs
(shRNAs)
We sub-cloned murine Fbln2-specific shRNAs (Sigma-
Aldrich, St. Louis, MO) and scrambled shRNA (Addgene,
plasmid 1864) into lentiviral pLKO.1 TRC (Addgene,
plasmid 10878). Additionally, pGIPZ lentiviral vectors
containing Fbln2-specific shRNA sequences
(V3LMM_515480 & V2LMM_26531) were purchased
(Open Biosystems, Lafayette, CO). The target
sequences for murine fibulin-2 were as follows: Fbln2
shRNA #1, GGAGCAGAGGACAATGATA; #2,
GCACTACCAGCTCAATTTC; #3,
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CCACTGTGTTCCTCAATTA; and #4,
CGTCTCACTCTACAAGCAA. These vectors were
packaged in 293T cells by co-transfection with
packaging vectors psPAX2 (Addgene, plasmid 12260)
and pMD2.G (Addgene, plasmid 12259). Cells (344SQ
and 531LN2) were infected with viral particles and
selected in puromycin (10 µg/mL) for up to 14 days to
generate stable transfectants.
Western blot analysis
Lysates from cell lines were harvested using RIPA
buffer and were separated by SDS-PAGE and
transferred onto a polyvinylidene fluoride nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA).
Membranes were blocked overnight at 4°C in TBST with
5% nonfat dry milk followed by incubation with primary
antibodies against fibulin-2 (Abcam, Cambridge, MA)
and beta-actin as an internal control in TBST with 2.5%
nonfat dry milk overnight at 4°C. Secondary antibodies
linked to HRP were incubated for 1 hour at room
temperature followed by detection with an enhanced
chemiluminescence kit according to the manufacturer’s
instructions (GE Healthcare, Pittsburgh, PA). Band
intensities were quantified based on densitometry
using ImageJ Software (http://rsbweb.nih.gov/ij/).
Reverse transcription-polymerase chain
reaction (RT-PCR) analysis
RNA was isolated from cells using Trizol Reagent
(Invitrogen, Grand Island, NY), and 2 µg of each RNA
sample was reverse-transcribed using qSCRIPT (Quanta
Biosciences, Gaithersburg, MD). Quantitative RT-PCR
analysis was performed using the ABI 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA)
using the comparative threshold method with
ribosomal protein L32 mRNA as an endogenous
reference housekeeping gene. For each reaction, a
standard curve was performed using serial dilutions of
a mixture of cDNA samples. SYBR green I (Applied
Biosystems) was used as the fluorophore. Non-
quantitative RT-PCR analysis of Fbln2 transcripts was
performed using Platinum Tag DNA polymerase
(Invitrogen) with L32 as a control. The primer
sequences used are listed in Table S1.
Cell proliferation in anchorage-dependent and
-independent conditions
For cell proliferation assay, 1000 cells were seeded in
96-well plates, and then WST-1 assay was carried out
at 4, 24, and 48 hours per manufacturer’s instructions
(Millipore, Billerica, MA) with colorimetric readings
taken at 450 nm. For anchorage independent cell
growth, cells (5 x 104 in 0.3% agar) were seeded onto a
layer of 0.8% agar in 6-well plates, allowed to
proliferate for 21 days, and stained with crystal violet.
Colonies were visualized by light microscopy and
scored per field of view.
Migration and invasion assays
Cells in serum-free RPMI 1640 (5 x 104) were seeded
onto Transwell plates (for migration; BD Biosciences,
San Jose, CA) or plates coated with growth-factor
reduced Matrigel (for invasion) in the presence of
mitomycin C (1 µg/mL), with RPMI 1640/10% FBS in the
lower well as the chemo-attractant. After 16-18 hours
of incubation, the medium was removed and the cells
were fixed with 90% ethanol. The migrated cells were
fixed, stained with 0.1% crystal violet, and then
counted under the microscope.
Cell adhesion assay
Cell adhesion on different ECM substrates was
examined using 96-well plates pre-coated in triplicate
with 5 µg/cm2 of corresponding ECM protein overnight
at 4°C. Wells were washed with PBS and blocked with
0.5% BSA for 1 hour at room temperature. Cells were
serum-starved for 1 hour prior to attachment assay at
which point they were trypsinized and resuspended in
serum free media at 5 x 104 cells/mL. Cell suspensions
(100 µL) were added to each well. Cells were allowed to
adhere for 1 hour at 37°C followed by fixation and
staining with 0.1% crystal violet, which was solubilized
in 10% acetic acid, and quantified at 595 nm
wavelength.
Immunofluorescence
For chamber slide immunofluorescence, cells were
cultured to confluence on 8-well glass Lab-Tek chamber
slides (Thermo Scientific, Waltham, MA) and fixed in
1% formaldehyde for 30 minutes followed by blocking
with serum-free protein block (DAKO) for 1 hour.
Chamber slides were stained for one hour at room
temperature with polyclonal rabbit antibodies against
collagen type IV (Abcam) or laminin (Abcam) and
rinsed in PBS (0.05% Tween 20). Sections were
incubated with donkey anti-rabbit Alexa 594
(Invitrogen). Chamber wells were removed and slides
were cover-slipped in Pro-Long Gold anti-fade mounting
media containing DAPI (Invitrogen).
Electron microscopy
Transmission electron microscopy was performed on
glutaraldehyde-fixed, plastic embedded subcutaneous
tumor tissue. The pseudopodial cytoplasmic projections
along with other cellular features were assessed
qualitatively at the ultrastructural level.
Mechanical testing
For analysis of tissue compressive properties, lung
disks of equal diameter were isolated by punch biopsy.
Sample dimensions were measured using digital
calipers prior to compression testing (n = 4 per
formulation). Compressive testing was performed using
an Instron Model 3340 mounted with a 10 N load cell.
Instron Series IX/s software was used for testing
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control, and data acquisition as uniaxial compressive
strain was applied at 0.2 mm/min. Force-elongation
data was converted to stress-strain data with corrected
cross-sectional area and plotted to derive the elastic
modulus from the slope of the linear portion of the
curve.
Total and pepsin cleaved collagen content of
cells in culture
Hydroxyproline measurements of total collagen were
conducted according to manufacturer’s instructions
(Cedar Lane Laboratories, Burlington, NC). Briefly,
equal cell densities were plated and allowed to reach
confluence for enhanced collagen deposition. Cell
homogenates were isolated in equal volumes of H2O
and diluted to a final concentration of 6 N HCl. Samples
were hydrolyzed by baking at 110°C for 24 hours at
which point floating lipid was removed and samples
were evaporated using speed vacuum without heat and
resuspend in equal volumes of H2O for subsequent
oxidation with chloramine-T and quantification using
DMAB substrate at 560 nm. Sircol measurements of
solubilized collagen were performed according to
manufacturer’s instructions (Biocolor, Carrickfergus,
UK). Solubilized collagen fragments from pepsin-
digested cell extracts (1 mg/mL gastric pepsin) were
detected by Picrosirius red substrate and acid-salt wash
followed by quantification at 555 nm.
Animal husbandry and syngeneic tumor cell
injections
As previously described [12], subcutaneous tumors
were generated in syngeneic (129/SV),
immunocompetent mice matched on the basis of age
(2 to 4 months) and gender by injecting KP cells (1 x
106) subcutaneously into the right flank in 100 µL PBS.
Mice were monitored daily for 6 weeks, at which time
necropsies were performed to isolate and weigh the
primary tumors and count lung metastases. Intra-
thoracic (orthotopic) injections were performed as
previously described [13]. Briefly, 129/SV syngeneic
mice (2 to 4 months) were injected in the left lung lobe
with 20,000 cells suspended in 50 µL of 1:10 diluted
growth-factor reduced Matrigel in Hanks’ balanced salt
solution (BD Biosciences). Mice were monitored daily
for 2 weeks, at which time necropsies were performed
to isolate and weigh the lung tissue and assess lymph
node metastasis.
Ethics statement
Before their initiation, all mouse experiments were
submitted to and approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Texas M D Anderson Cancer Center (#02-09-01732).
Mice received standards of care and were euthanized
according to the standards set forth by the IACUC. A
protocol to perform research on human tissues was
submitted to the Office of Protocol Research and was
reviewed, approved, and sanctioned by the Institutional
Review Board of the University of Texas M D Anderson
Cancer Center. Written informed consent was obtained
from each patient.
Statistical analysis
Statistical significance was determined by Student’s
t-test. The difference was considered signiﬁcant at P <
0.05 (two-tailed).
Results
Distinct fibulin-2 expression patterns in
human lung adenocarcinoma
We examined whether fibulin-2 is expressed in
human lung adenocarcinomas. Fibulin-2 was quantified
by immunohistochemical analysis of 46 primary lung
adenocarcinomas and adjacent lung tissues. Fibulin-2
was detected in elastic tissues within bronchi and
vascular structures in adjacent normal lung (Figure 1A),
in a “fibrillar” pattern between tumor cells and
surrounding tumor acini, and in a “fibrotic” pattern
within intra-tumoral fibrotic bands (Figure 1B). Most
tumors exhibited both patterns; fibrillar staining was
detected in all 46 tumors and fibrotic staining in 40.
Fibulin-2 drives lung adenocarcinoma
progression
Fibulin-2 was detectable in spontaneous lung tumors
in KP mice (Figure 2A) and in KP cells (Figure 2B).
Western blotting of fibulin-2 in KP cells revealed two
bands with molecular weights of approximately 190 kD
and 150 kD; by densitometric analysis, the larger band
was more abundant in metastatic KP cell lines (344SQ,
531LN2, 531LN3, and 344P) than it was in non-
metastatic KP cell lines (307P, 393P, and 412P) (Figure
2B). Fbln2 alternative splicing yields a transcript
lacking exon 9 and generates a protein product 5 kD
smaller than full-length fibulin-2 [5,6,8], whereas the
two bands observed on fibulin-2 western blotting
differed by approximately 40 kD (Figure 2B). Moreover,
KP cells expressed a single Fbln2 transcript that lacked
exon 9 (Figure 2C), consistent with the presence of
spliced but not full-length transcripts, arguing against
differential alternative splicing in metastatic and non-
metastatic KP cells.
To examine the role of fibulin-2 in lung
tumorigenesis, two different metastatic KP cells (344SQ
and 531LN2) were stably transfected with Fbln2-
specific and scrambled shRNAs to generate fibulin-2-
deficient and control transfectants, respectively (Figure
2D and E, and Figure S1). The transfectants were
injected into syngeneic wild-type mice subcutaneously
to generate flank tumors that metastasize
predominately to the lungs (Figure 3A and B), or intra-
thoracically to create orthotopic lung tumors that
metastasize predominately to mediastinal nodes
Fibulin-2 Drives Malignant Progression
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(Figure 3C and D) [12,13]. Relative to controls, the
fibulin-2-deficient tumors were significantly smaller and
produced fewer metastases regardless of injection site
(Figure 3A–D).
Figure 1.  Distinct patterns of fibulin-2 expression in human lung adenocarcinomas and correlation
with clinical outcome.  Anti-fibulin-2 immunohistochemical staining (brown) of normal human lung adjacent to
the tumor (A) and two different primary human lung adenocarcinomas representative of fibrillar (B, left panel) and
fibrous (B, right panel) staining patterns. Size bars are indicated.
doi: 10.1371/journal.pone.0067054.g001
Figure 2.  Fibulin-2 expression in murine lung adenocarcinomas and creation of fibulin-2-deficient
cells.  (A) A representative image of anti-fibulin-2 immunohistochemical staining (brown) in a spontaneous lung
adenocarcinoma from a KP mouse. (B) Western blot analysis of fibulin-2 expression in metastatic (344SQ, 344P,
531LN2, and 531LN3) and non-metastatic (393P, 307P, and 412P) KP cell lines. Two fibulin-2 species were identified
that differ on the basis of molecular weight (190 kD and 150 kD). β-actin included as loading control. Densitometric
analysis of 190 kD band in western blot normalized on the basis of β-actin (bar graph). (C) Non-quantitative RT-PCR
analysis of ribosomal protein L32 (left) and Fbln2 transcripts. (D and E) Quantitative RT-PCR (bar graph) and
western blot (gels) assays on 344SQ cells (D) and 531LN2 cells (E) stably transfected with scrambled control shRNA
(SCR) or one of four distinct Fbln2 shRNAs (#1, #2, #3 or #4). RT-PCR values normalized on the basis of ribosomal
protein L32 mRNA and expressed as the mean values (± S.D.) of quadruplicate samples.
doi: 10.1371/journal.pone.0067054.g002
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Other intra-tumoral cell types such as fibroblasts,
normal epithelial cells, and endothelial cells are known
to express fibulin-2 [14,15]. To determine whether
other cellular sources of fibulin-2 play a biological role
during malignant progression, 344SQ cells were
injected into Fbln2-null and -wild-type littermates [16].
Orthotopic lung tumors grew and metastasized in the
setting of both genotypes (Figure 3E). Thus, malignant
progression was dependent specifically upon tumor
cell-derived fibulin-2, which could not be offset by other
cellular sources of fibulin-2.
On the basis of the above findings, we posited that
tumor cell-derived fibulin-2 promotes the migratory,
invasive, and proliferative capacity of tumor cells and
performed in vitro studies on fibulin-2-deficient cells to
test this hypothesis. Compared to controls, fibulin-2-
deficient cells were less proliferative in monolayer
cultures (Figure 4A), formed fewer colonies in soft agar
(Figure 4B), displayed reduced migration in wound-
healing assays (Figure 4C), and exhibited diminished
migration and invasion in Boyden chambers (Figure
4D). Transmission electron microscopic analysis of
control tumors revealed abundant pseudopodia and
heterochromatin (Figure 5A), which were less abundant
in fibulin-2-deficient tumors (Figure 5B), reflecting a
loss of invasive and proliferative properties,
respectively. Thus, fibulin-2 enhanced tumor cell
proliferation, migration, and invasion, which could have
mediated its promotion of tumorigenesis and
metastasis.
Figure 3.  Fibulin-2 promotes the growth and metastatic properties of KP cells.  (A–C) Transfectants (1 x
106) injected into the flank of syngeneic wild-type mice (n=10 per cohort) to generate subcutaneous tumors. Mice
sacrificed after 6 weeks to weigh primary tumor (left bar graphs in A and B) and count visible lung metastases
(right bar graphs in A and B). Scatter plot representation of each tissue sample (squares), mean values (long line)
and standard deviations (short line). P-values are indicated (t-test). Representative images of subcutaneous (SQ)
tumors and lung metastases (C). (D) Syngeneic wild-type mice (n=10 per cohort) were injected intra-thoracically
with transfectants (2 x 104) to generate a single orthotopic lung tumor. Mice were sacrificed after 2 weeks to weigh
left lung (bearing tumor) and determine the presence or absence of metastases to mediastinal lymph nodes.
Scatter plot representation of each tissue sample (squares), mean values (long line) and standard deviations (short
line). P-values are indicated (t-test). Percentages of mice in each cohort with metastases to mediastinal lymph
nodes (bar graph). (E) Fbln2-null (-/-) and -wild-type (+/+) mice were injected intra-thoracically with 344SQ cells (2
x 104) to generate a single orthotopic lung tumor and analyzed as described in (D). P-values are indicated (t-test).
doi: 10.1371/journal.pone.0067054.g003
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Figure 4.  Fibulin-2 promotes 344SQ cell proliferation, migration, and invasion.  (A) Cell proliferation
(WST-1) assays to quantify relative cell density of transfectants grown in monolayer cultures. Results expressed as
mean values of triplicate wells (± S.D.) at each time point. Asterisks indicate P < 0.01, SCR shRNA versus Fbln2
shRNA. (B) Colonies of transfectants grown in soft agar were photographed and counted after 21 days. Results
expressed as mean values (± S.D.) of triplicate wells (bar graph). (C) Images of confluent cultures subjected to
scratch-wounds after 16 hours. (D) Migration and invasion assays of transfectants loaded into upper chambers of
Boyden apparatus in the presence of 10% serum in bottom chamber as chemo-attractant and 1 µg/mL mitomycin C
to block cell proliferation. Cells migrating or invading through the filters were stained with crystal violet,
photographed, and quantified. Results represent the mean values (± S.D.) of quadruplicate samples (bar graph). P-
values are indicated (t-test).
doi: 10.1371/journal.pone.0067054.g004
Figure 5.  Fibulin-2 deficiency reduces tumor cell pseudopodia.  Transmission electron microscopic images
of subcutaneous tumors transfected with scrambled shRNA (A) or Fbln2 shRNA (B). Pseudopodia (enclosed by
dotted red line) and heterochromatin (arrow) are indicated.
doi: 10.1371/journal.pone.0067054.g005
Fibulin-2 Drives Malignant Progression
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e67054
Fibulin-2 promotes cross-linking of secreted
collagen and tumor cell adherence to collagen
Fibulin-2 is a nidogen-interacting protein and binds to
the nidogen-like domain of MUC4, an interaction that
has been implicated as a mediator of MUC4-induced
invasion [17]. Given that MUC4 expression was
detectable in KP cells (Figure S2), we examined
whether fibulin-2 forms a complex with MUC4.
However, MUC4 did not co-immunoprecipitate with
fibulin-2 (Figure S2). Although physical interactions
may occur at levels not detectable by this assay, these
findings argue against a role for MUC4/fibulin-2
complexes in this model.
Invasion into adjacent stroma requires that tumor
cells create mature extracellular matrix fibers and
adhere to and migrate along those fibers [2]. We
examined whether fibulin-2 deficiency abrogated the
ability of tumor cells to perform these functions.
Compression testing was performed on fibulin-2-
deficient and -replete orthotopic lung tumors to
quantify tissue stiffness, an indirect measure of cross-
linked collagen, which revealed that stiffness was
reduced in fibulin-2-deficient tumors (Figure 6A).
Quantification of collagen concentrations in conditioned
media samples from fibulin-2-deficient and -replete
cells revealed no difference in total collagen, but
soluble collagen was significantly more abundant in
fibulin-2-deficient cells (Figure 6B), reflecting a
reduction in cross-linked collagen. Analysis of enzymes
that control collagen cross-linking revealed that Loxl2
and Loxl4 were the most abundantly expressed, and
fibulin-2 deficiency reduced the expression of Loxl4 but
paradoxically increased Loxl2 (Figure 6C). We
examined tumor cell adherence to matrix molecules by
seeding 344SQ cells in wells pre-coated with collagen
type I, collagen type IV, laminin, or fibronectin. Cells
adhered to collagen type I but not the other matrix
molecules, and adherence to collagen type I was
abrogated by fibulin-2 depletion (Figure 6D).
Quantification of integrins that bind collagen (α1β1,
α2β1, α10β1, and α11β1) [18] revealed significant
reductions in Itga1, Itga2, Itga10, and Itgb1 in fibulin-2-
deficient 344SQ cells (Figure 6E). Collectively, these
findings suggest that tumor cells required fibulin-2 for
the creation of a stiff extracellular matrix and
adherence to collagen.
Discussion
Here we posited that fibulin-2, a matrix glycoprotein
that functions biomechanically as an inter-molecular
clasp, stabilizes tumor extracellular matrix and thereby
drives malignant progression. We showed that fibulin-2
was abundant in the extracellular matrix of human lung
adenocarcinomas and was distributed in two different
intra-tumoral patterns, “fibrillar” and “fibrotic”,
suggesting that fibulin-2 may have multiple cellular
origins and biological roles. Fibulin-2 was abundantly
expressed in metastatic cells from a mouse model of
human lung adenocarcinoma and was required for
metastatic behaviors of these cells.
Most studies on the role of fibulin-2 in cancer have
shown that it functions as a tumor suppressor. The
FBLN2 gene is silenced through methylation or deletion
in various tumor types, and reintroduction of fibulin-2
into cancer cells that do not express fibulin-2 reduces
motility and invasion in vitro [19–22]. The evidence
reported here is the first, to our knowledge, to show
that fibulin-2 is a driver of malignant progression.
Although these experimental findings are unique, they
are consistent with reports that fibulin-2 is part of a
gene expression signature in primary epithelial tumors
that predicts the presence of occult metastasis, and
that fibulin-2 may promote the metastatic potential of
pancreatic cancer cells through its interactions with
MUC4 [10,17]. Thus, fibulin-2 plays a more complex
role in cancer than had been previously appreciated.
Fibulin-2 consists of four domains, including the N-
terminal domain, three anaphylatoxin modules, a
tandem of epidermal growth factor (EGF)-like repeats,
and the C-terminal fibulin-type module [8]. In humans
and mice, the third EGF-like repeat is either present or
absent as a result of alternative splicing in exon 9, and
both fibulin-2 isoforms are protein coding [23]. In
studies on patients with nasopharyngeal cancer, the
spliced fibulin-2 isoform (FBLN2S) is expressed in
adjacent normal tissues, is silenced in primary tumor
tissues and nasopharyngeal cancer cell lines, is
selectively re-expressed in cell lines following 5-
azacytidine treatment, and exerts tumor suppressor
activity when reintroduced into cells [20]. In KP cells,
fibulin-2 western blotting revealed two bands, but
analysis of Fbln2 transcripts revealed only the spliced
form, and depletion of fibulin-2 abrogated tumor
growth and metastasis, which stands in contrast to
tumor suppressor effects of fibulin-2 reported
previously [20]. Although the basis for these conflicting
findings is unclear, a potential contributor includes cell
type-specific biological roles of fibulin-2 in lung and
nasopharyngeal cancer cells.
Here we showed that fibulin-2 promotes cross-linking
of secreted collagen molecules and tumor cell
adherence to collagen, biochemical functions that are
presumably unrelated to its structural role as a bridge
between matrix molecules [5]. However, the
mechanisms by which fibulin-2 performed these
biochemical functions are unclear. Fibulin-2 does not
associate with collagen type I [24], arguing against a
direct role for fibulin-2 in the enzymatic or non-
enzymatic steps involved in collagen processing [2].
Unlike tenascin C and periostin, matrix proteins that
function as ligands for integrins and other membrane
receptors and activate Wnt signaling [25–27], fibulin-2
has no known receptor-binding activity or proven role
in the regulation of intracellular signaling.
Nevertheless, the prominent effect of fibulin-2
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deficiency on gene expression shown here (increased
Loxl2 and decreased collagen-binding integrins and
Loxl4) implies that fibulin-2 has intracellular roles that
have not yet been uncovered.
Supporting Information
Table S1.  RT-PCR primer sequences.
(PDF)
Figure S1.  Immunofluorescence staining of
fibulin-2 in 344SQ cells stably transfected with
control (SCR) or Fbln2 shRNA #1. Anti-fibulin-2
(red) and DAPI (blue).
(TIF)
Figure S2.  Co-immunoprecipitation of fibulin-2
and MUC4 in 344SQ cells. After
immunoprecipitation with anti-fibulin-2 antibody,
western blotting was performed by using anti-
fibulin-2 or MUC4 antibodies.
(TIF)
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